{"id":270,"date":"2025-06-11T14:55:17","date_gmt":"2025-06-11T14:55:17","guid":{"rendered":"https:\/\/analizesanocare.ro\/?post_type=product&#038;p=270"},"modified":"2025-08-08T13:56:22","modified_gmt":"2025-08-08T13:56:22","slug":"ihc-ros1","status":"publish","type":"product","link":"https:\/\/analizesanocare.ro\/en\/analiz\u0103\/ihc-ros1\/","title":{"rendered":"IHC ROS1"},"content":{"rendered":"<div class=\"info-content content-informatii-generale\">\n<h2><strong>\u00a0Informa\u021bii generale \u2013 IHC ROS1<\/strong><\/h2>\n<p><a href=\"https:\/\/www.synevo.ro\/cancer-pulmonar-epidemiologie-diagnostic\/\" data-wpel-link=\"internal\">Cancerul pulmonar<\/a> este o boala extrem de agresiv\u0103, produc\u00e2nd peste 1.8 milioane de decese anual, fiind astfel pricipala cauz\u0103 de mortalitate prin cancer, la nivel mondial. At\u00e2t persoanele fumatoare, c\u00e2t \u0219i cele nefumatoare au un risc crescut de apari\u021bie a acestui tip de cancer.<\/p>\n<p>Riscul de cancer cre\u0219te odat\u0103 cu perioada scurs\u0103 de la ini\u021bierea obiceiului de a fuma, dar \u0219i cu num\u0103rul de \u021bigarete fumate, pe zi.<\/p>\n<p>\u00cen func\u021bie de aspectul microscopic, cancerul pulmonar este clasificat \u00een doua forme:<\/p>\n<ul>\n<li>cancer pulmonar cu celule mici (SCLC)<\/li>\n<li><a href=\"https:\/\/www.synevo.ro\/informatii-medicale\/cancer-pulmonar-non-microcelular\/\" data-wpel-link=\"internal\">cancer pulmonar f\u0103r\u0103 celule mici (NSCLC)<\/a><\/li>\n<\/ul>\n<p>NSCLC reprezint\u0103 85% din totalul cancerelor pulmonare, cele mai frecvente subtipuri din aceasta clasa fiind: carcinomul scuamos, carcinomul cu celule mari si adenocarcinomul.<\/p>\n<h3><strong>Evaluarea activit\u0103\u021bii GENEI ROS1 \u00een NSCLC<\/strong><\/h3>\n<p><strong>\u00a0<\/strong>Gena ROS1 (c-ros oncogene 1) este localizat\u0103 pe bra\u021bul lung al cromozomului 6 (6q22) \u0219i codific\u0103 o protein\u0103 membranar\u0103 integral\u0103 de tip I, <strong>ROS1 (Represor of Silence), <\/strong>cu rol de receptor cu activitate de tip tirozinkinazic\u0103. Muta\u021bii ale genei ROS1 determin\u0103 sinteza unor proteine al c\u0103ror domeniu kinazic devine constitutiv activ, activ\u00e2nd o serie de c\u0103i de semnalizare oncogenic\u0103, care vor controla proliferarea, supravie\u021buirea \u0219i semnalizarea celular\u0103. Astfel <strong>inhibarea activit\u0103\u021bii <\/strong>acestor enzime <strong>este o terapie eficient\u0103 \u00eempotriva cancerului.<\/strong><\/p>\n<p>Rearanjamentele genei ROS1 sunt raportate \u00een 1 \u2013 2% dintre adenocarcinoamele pulmonare, nu sunt mo\u0219tenite sau prezente la na\u0219tere \u0219i sunt asociate cu o rat\u0103 de r\u0103spuns mai mare la anumite terapii.<\/p>\n<p>La unii pacien\u021bi cu cancer pulmonar gena ROS1 fuzioneaz\u0103 cu por\u021biuni ale altor tipuri de gene, cea mai frecvent\u0103 fiind cea cu gena CD74. Fuziunea CD74-ROS1 este implicat\u0103 \u00een carcinogeneza tumorilor pulmonare f\u0103r\u0103 celule mici, glioblastom, angiosarcom, colangio-carcinom, cancer colorectal, hemangio- endoteliom epitelioid, adenocarcinom gastric, glioblastom, tumor\u0103 miofibroblastic\u0103 inflamatorie, cancer ovarian. Alti parteneri de fuziune pot fi genele ALK \u0219i RET. \u00cen prezent, sunt cunoscu\u021bi 27 de parteneri de fuziune genic\u01039.<\/p>\n<p>Studii clinice actuale arat\u0103 c\u0103 adenocarcinomul pulmonar cu rearanjare ROS1 este sensibil la actiunea terapiei cu CRIZOTINIB, av\u00e2nd o rat\u0103 de r\u0103spuns de peste 70%. Aceast\u0103 terapie este aprobat\u0103 pentru tratamentul NSCLC cu confirmare a rearanj\u0103rii genice ROS1, iar ghidurile actuale recomand\u0103 ca to\u021bi pacien\u021bii diagnostica\u021bi cu adenocarcinom pulmonar s\u0103 fie testa\u021bi pentru ROS1.<\/p>\n<p><strong>Indica\u0163iile terapiei cu CRIZOTINIB<sup>7<\/sup>:<\/strong><\/p>\n<ol>\n<li><strong>\u00a0<\/strong>Tratamentul de prima intentie al adul\u0163ilor cu carcinom bronho-pulmonar, altul dec\u00e2t cel cu celule mici (NSCLC) avansat, pozitiv pentru kinaza limfomului anaplazic (<strong>ALK pozitiv<\/strong>).<\/li>\n<\/ol>\n<ol start=\"2\">\n<li>Tratamentul adul\u0163ilor cu neoplasm bronho-pulmonar, altul dec\u00e2t cel cu celule mici (NSCLC) avansat, tratat anterior, pozitiv pentru kinaza limfomului anaplazic (<strong>ALK pozitiv<\/strong>)<\/li>\n<li>Tratamentul adul\u0163ilor cu neoplasm bronho-pulmonar, altul dec\u00e2t cel cu celule<\/li>\n<\/ol>\n<p>\u00cen cancerul NSCLC avansat, testarea ROS1 este indicat\u0103 \u0219i \u00een vederea ini\u021bierii terapiei cu alte molecule, cum ar fi Entrectinib (de preferat) \u0219i Ceritinib.<\/p>\n<p><strong>Specimen recoltat:<\/strong><strong>\u00a0<\/strong><\/p>\n<ul>\n<li>fragmentele tisulare fixate \u00een formol 10%;<\/li>\n<li>blocuri de parafin\u0103.<\/li>\n<\/ul>\n<p><strong>Metoda de lucru: <\/strong>Testele imunohistochimice se efectuez\u0103 \u00een sistem complet automat, utiliz\u00e2nd sistemul BenchMark ULTRA (Ventana), cu respectarea protocoalelor recomandate de produc\u0103tor.<\/p>\n<p>Colora\u021bia imunohistochimic\u0103 tip ROS1 (clona SP384) folose\u0219te un anticorp monoclonal produs \u00eempotriva proteinei codificate de gena ROS1, un receptor tip tirozin kinaz\u0103 (RTK). Reac\u021bia IHC se eviden\u021biaz\u0103 \u00een principal la nivel citoplasmatic \u0219i rar, membranar \u0219i nuclear.<\/p>\n<p><strong>Recipient de recoltare:<\/strong><\/p>\n<ul>\n<li><strong>\u00a0<\/strong>recipiente cu formol tamponat 10% (adaptate pentru dimensiunile fragmentelor tisulare recoltate)<\/li>\n<\/ul>\n<p><strong>Stabilitate proba:\u00a0<\/strong><strong>\u00a0<\/strong><\/p>\n<ul>\n<li>fragmentele tisulare fixate \u00een formol 10%, 24-72 ore<\/li>\n<li>blocuri de parafin\u0103 \u2013 \u00een mediu ambiental, protejate de umezeal\u0103 \u0219i radia\u021biile solare<\/li>\n<\/ul>\n<h2><strong>Interpretarea rezultatelor:<\/strong><\/h2>\n<p><strong>\u00a0<\/strong>Raportul furnizeaz\u0103 informa\u021bii despre clona de anticorpi utilizat\u0103 \u0219i confirm\u0103\/infirm\u0103 supraexpresia tip ROS1. Pe lam\u0103, ROS1 va colora pneumocitele de tip II non-neoplazice din \u021besutul s\u0103n\u0103tos \u0219i tumoral8.<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone wp-image-483287\" src=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2023\/03\/IHC-ROS1-300x156.jpg\" sizes=\"(max-width: 400px) 100vw, 400px\" srcset=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2023\/03\/IHC-ROS1-300x156.jpg 300w, https:\/\/www.synevo.ro\/wp-content\/uploads\/2023\/03\/IHC-ROS1-768x399.jpg 768w, https:\/\/www.synevo.ro\/wp-content\/uploads\/2023\/03\/IHC-ROS1-600x312.jpg 600w, https:\/\/www.synevo.ro\/wp-content\/uploads\/2023\/03\/IHC-ROS1.jpg 832w\" alt=\"IHC ROS1 - Synevo\" width=\"400\" height=\"208\" \/>\u00a0Colora\u021bie cu intensitate 0 (no staining)<\/p>\n<p>Rezultatul ob\u021binut cu testului ROS1 trebuie integrat cu alte teste, \u00een raportul histopatologic, pentru cazurile diagnosticate cu NSCLC.<\/p>\n<p>Colora\u021bia IHC ROS1 are o sensibilitate de 100% \u0219i o specificitate de 92%, comparativ cu tehnica ISH tip FISH, ceea ce o face un instrument eficient \u00een screening-ul pacientilor, pentru selectarea terapiei moleculare, \u00een adenocarcinomul pulmonar7.<\/p>\n<h2><strong>Referinte<\/strong>:<\/h2>\n<ol>\n<li>Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signalling identifies oncogenic kinases in lung cancer. Cell 2007; 131, 1190-1203.<\/li>\n<li>Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO Consensus Conference on Lung Cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014; 25, 1681-90<\/li>\n<li>FDA News Release: FDA expands use of Xalkori to treat rare form of advanced non-small cell<\/li>\n<li>lung Page visited last time on 18 April 2016.<\/li>\n<li>Package Insert, VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody, English<\/li>\n<li><a href=\"https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/lung-cancer\/symptoms-diagnosis\/biomarker-testing\/ros1\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/lung-cancer\/symptoms-diagnosis\/biomarker-testing\/ros1<\/a><\/li>\n<li><a href=\"https:\/\/ema.europa.eu\/en\/documents\/product-information\/xalkori-epar-product-information_ro.pdf\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/ema.europa.eu\/en\/documents\/product-information\/xalkori-epar-product-information_ro.pdf<\/a><\/li>\n<li><a href=\"https:\/\/nature.com\/articles\/modpathol2013192\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/nature.com\/articles\/modpathol2013192<\/a><\/li>\n<li><a href=\"https:\/\/rochebiomarkers.be\/content\/media\/Files\/ROS1_IHC_guide_version_1.pdf\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/rochebiomarkers.be\/content\/media\/Files\/ROS1_IHC_guide_version_1.pdf<\/a><\/li>\n<\/ol>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>\u00a0Informa\u021bii generale \u2013 IHC ROS1 Cancerul pulmonar este o boala extrem de agresiv\u0103, produc\u00e2nd peste 1.8 milioane de decese anual, fiind astfel pricipala cauz\u0103 de mortalitate prin cancer, la nivel mondial. At\u00e2t persoanele fumatoare, c\u00e2t \u0219i cele nefumatoare au un risc crescut de apari\u021bie a acestui tip de cancer. Riscul de cancer cre\u0219te odat\u0103 cu [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[112,50],"product_tag":[],"class_list":["post-270","product","type-product","status-publish","product_cat-coloratii-speciale","product_cat-histopatologie","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"_links":{"self":[{"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product\/270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/types\/product"}],"wp:attachment":[{"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/media?parent=270"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product_brand?post=270"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product_cat?post=270"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product_tag?post=270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}